Angioplasty

El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

Ticagrelor Shows Benefits in Coronary Microvascular Function after NSTEMI

Coronary microvascular disfunction (CMD) is an important long-term prognosis predictor. CMD treatment can be an effective therapeutic strategy for patients with acute coronary syndrome (ACS). Nevertheless, more studies are needed to assess different strategies. In the PLATO (Study of Platelet Inhibition and Patient Outcomes) study, ticagrelor vs. clopidogrel reduced ischemic events and overall mortality in<a href="https://solaci.org/en/2022/04/21/ticagrelor-shows-benefits-in-coronary-microvascular-function-after-nstemi/" title="Read more" >...</a>

Carotídeas asintomáticas ¿Tenemos todas las respuestas?

Is iFR Reliable After 5 Years? Analyzing the iFR-SWEDEHEART at 5 Years

Fractional flow reserve (FFR) proved to be very useful and safe in the FAME study, but its trade-off was using adenosine (which has a short half-life) and adverse reactions, which fortunately were rare. Subsequently, two large studies—the iFR-SWEDEHEART and DEFINE-FLAIR—demonstrated that instantaneous wave-free ratio (iFR) offered comparable results to FFR in the short term, avoiding<a href="https://solaci.org/en/2022/04/19/is-ifr-reliable-after-5-years-analyzing-the-ifr-swedeheart-at-5-years/" title="Read more" >...</a>

ACC 2022

ACC 2022 | FLAVOUR Study: FFR and IVUS in Intermediate Coronary Lesions

FLAVOUR was a prospective randomized non-inferiority study in patients with intermediate coronary lesions (40%-70%) that compared two imaging modalities: IVUS (intravascular imaging) and FFR (fractional flow reserve).&nbsp; According to this research—presented at ACC 2022—, FFR-guided angioplasty was non-inferior to IVUS-guided angioplasty at 2 years of follow-up. Furthermore, using FFR-based imaging led to fewer stent implantations.<a href="https://solaci.org/en/2022/04/13/acc-2022-flavour-study-ffr-and-ivus-in-intermediate-coronary-lesions/" title="Read more" >...</a>

SOLACI Peripheral Registry Surpassed the 500-Patient Mark

We are glad to announce that the Latin American SOLACI Peripheral Registry keeps growing and has enrolled over 500&nbsp;patients. Over 9 countries and 29 Latin American sites have joined this multicenter, prospective research initiative that aims to collect data on the reality of lower limb angioplasty within our continent, in order to unify criteria, draw<a href="https://solaci.org/en/2022/04/08/solaci-peripheral-registry-surpassed-the-500-patient-mark/" title="Read more" >...</a>

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

CRUNCH Registry: An Option for Underexpanded Stents

Coronary calcification hinders both stent transfer and implantation, and has been associated with a higher risk of complications. Coronary perforation is the worst of them. In turn, these calcifications affect the preparation of coronary plaque, resulting in an underexpanded stent (US), which is a strong predictor of restenosis and early thrombosis. For the management of<a href="https://solaci.org/en/2022/04/08/crunch-registry-an-option-for-underexpanded-stents/" title="Read more" >...</a>

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

Should We Start Stenting with DES in Femoropopliteal Territory?

Percutaneous intervention of femoropopliteal lesions have been the standard strategy these past two decades. The development of drug eluting stents (DES) or drug eluting balloons (DEB) has improved patency rate compared against conventional balloon angioplasty. The ILLUMINA -a multicenter study- looked into the polymer free self-expanding stent NiTiDES, which showed at 1 year an 87%<a href="https://solaci.org/en/2022/04/07/should-we-start-stenting-with-des-in-femoropopliteal-territory/" title="Read more" >...</a>

¿Hay diferencias entre mujeres y hombres luego de una intervención percutánea?

Are There Differences Between Women and Men After a Percutaneous Intervention?

Prior research has shown that women with coronary artery disease who undergo percutaneous revascularization present more comorbidities, require less aggressive treatments, have greater long-term morbidity rates and worst functional status and/or post-procedure angina. This study used data from the CPORT-E trial (Cardiovascular Patient Outcomes Research Team Non primary Percutaneous Coronary Intervention) to assess baseline differences<a href="https://solaci.org/en/2022/04/04/are-there-differences-between-women-and-men-after-a-percutaneous-intervention/" title="Read more" >...</a>

stent

STEMI: Can We Omit Stenting?

The recommended treatment for ST elevation acute myocardial infarction (STEMI) is early PCI, typically stenting. However, stent implantation always involves the risk of intravascular complications, such as stent thrombosis or restenosis.&nbsp;&nbsp; Sometimes stable flow is restored to the target vessel after initial PCI and we can omit stenting when there is no angiographically significant residual<a href="https://solaci.org/en/2022/04/04/stemi-can-we-omit-stenting/" title="Read more" >...</a>

La FDA aprueba el ticagrelor en pacientes de alto riesgo como prevención primaria

Abbreviated DAPT in ACS: The End of Clopidogrel Monotherapy?

Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to suffer from long term major adverse cardiac events (MACE). To prevent this, both the American and the European guidelines recommend prolonging dual antiplatelet therapy (DAPT) in this population for at least 12&nbsp;months. However, in patients with certain clinical<a href="https://solaci.org/en/2022/03/21/abbreviated-dapt-in-acs-the-end-of-clopidogrel-monotherapy/" title="Read more" >...</a>

reserva fraccional de flujo sindrome coronario agudo

Zwolle Score: Can a Risk Score Decide Where STEACS Patients Should Stay?

The mortality of ST-segment elevation acute coronary syndromes (STEACS) has decreased thanks to improved reperfusion times (fibrinolysis or primary angioplasty), so that, in daily practice, there is a greater number of patients with stable acute myocardial infarction (AMI). This clinical stability and a low rate of complications raise the question of whether performing triage is<a href="https://solaci.org/en/2022/03/16/zwolle-score-can-a-risk-score-decide-where-steacs-patients-should-stay/" title="Read more" >...</a>

Top